REG - Genedrive PLC - Completion of Placing

GenedriveAnnouncement

13/02/2026 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260213:nRSM0154Ta&default-theme=true

RNS Number : 0154T  Genedrive PLC  13 February 2026

13 February 2026

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN
OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO
DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR
REGULATION.

FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY
OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO
ANY PERSON SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN GENEDRIVE PLC IN ANY
JURISDICTION.

genedrive plc

("genedrive", the "Group" or the "Company")

Completion of Placing

Manchester, UK - 13 February 2026: genedrive plc (LSE: GDR), the point of care
pharmacogenetic testing company, announces the completion of the placing (the
"Placing") which was announced earlier today.  The new ordinary shares to be
allotted pursuant to the Placing are to be issued at an issue price of 1.0
pence per share (the "Issue Price").  The Company also announced a proposed
direct subscription at the Issue Price (the "Subscription", incorporating a
Firm Subscription and Conditional Subscription) to raise £3.5 million and
that it will also be making an Open Offer to Qualifying Shareholders, also at
the Issue Price, to raise up to approximately £1.5 million (the "Open
Offer"), which together with the Placing and the Subscription is the
"Fundraising".

The Company announces that it has successfully placed 50,000,000 Placing
Shares at the Issue Price resulting in gross proceeds of £500,000.

The Fundraising (excluding the Firm Subscription) is conditional on, inter
alia, the passing of the Resolutions by Shareholders at a general meeting of
the Company which will be convened in due course (the "General Meeting"). The
Company expects to post the Circular, including the notice of General Meeting
in the coming days.

It is expected that the Placing will complete on or around 8.00 a.m. on 10
March 2026, being the expected date of Admission of the Placing Shares.  The
Placing is also conditional upon the Placing and Open Offer Agreement between
the Company and Peel Hunt becoming unconditional and not being terminated in
accordance with its terms.

The Subscription Shares, Placing Shares, Loan Conversion Shares and Open Offer
Shares will, when issued, be credited as fully paid and will be issued subject
to the Company's articles of association and will rank pari passu in all
respects with the existing issued ordinary shares in the capital of the
Company, including the right to receive all dividends and other distributions
declared, made or paid on or in respect of such shares by reference to a
record date falling after their issue.

Applications will be made to the London Stock Exchange for the Firm
Subscription Shares, Conditional Subscription Shares, Placing Shares, Loan
Conversion Shares and Open Offer Shares as may be subscribed for to be
admitted to trading on AIM (each an "Admission"). It is expected that
Admission of the Firm Subscription Shares will occur at 8.00 a.m. on 18
February 2026. It is expected that Admission of the Conditional Subscription
Shares, Placing Shares, Loan Conversion Shares and Open Offer Shares as are
subscribed for will occur at 8.00 a.m. on 10 March 2026 (or such later date as
the Company and Peel Hunt may agree, being no later than 8.00 a.m. on 31 March
2026).

General Meeting

The Circular containing a notice convening the General Meeting will be posted
to Shareholders over the coming days.  The General Meeting is expected to be
convened for a date in early March.  Further details will be set out in the
Circular including the timetable for the Open Offer.

Open Offer to Qualifying Shareholders

In order to provide Shareholders who do not take part in the Subscription or
Placing with an opportunity to participate in the Fundraising, the Company
intends to make an Open Offer to Qualifying Shareholders on the terms and
conditions to be set out in the Circular. The Open Offer provides Qualifying
Shareholders with the opportunity to subscribe at the Issue Price for an
aggregate of up to 149,760,580 Open Offer Shares to raise up to approximately
£1.5 million (before fees and expenses) for the Company, on the basis of:

8 Open Offer Shares for every 55 Ordinary Shares held as at the Record Date.

Conditions and right of termination of the Placing

The Placing is conditional upon the Placing and Open Offer Agreement becoming
unconditional in respect of the Placing and not having been terminated in
accordance with its terms. The Bookrunner's obligations in respect of the
Placing and Open Offer Agreement are conditional on customary conditions (the
"Conditions"), including (amongst others):

1.              certain announcement obligations;

2.             Admission of the Placing Shares occurring no later than
8.00 a.m. (London time) on 10 March 2026 (or such later time and/or date, not
being later than 8.00 a.m. (London time) on 31 March 2026 as the Bookrunner
may otherwise agree with the Company);

3.           the passing of the shareholder resolutions in the approved
terms to be set out in the notice convening the General Meeting;

4.             none of the warranties contained in the Placing and Open
Offer Agreement, in the opinion of the Bookrunner (acting in good faith),
being untrue or inaccurate or misleading at the date of the Placing and Open
Offer Agreement or becoming untrue or inaccurate or misleading at any time
between such date and Admission of the Placing Shares by reference to the
facts and circumstances from time to time subsisting;

5.             the Company having complied with all of its obligations
under the Placing and Open Offer Agreement which fall to be performed or
satisfied on or prior to Admission of the Placing Shares;

6.              the Admission of the Firm Subscription Shares having
taken place;

7.              the execution and delivery of the Placing Supplement;
and

8.              in the opinion of the Bookrunner (in good faith), there
having been no Material Adverse Change.

If: (i) any of the Conditions are not fulfilled or (where permitted) waived
by the Bookrunner by the relevant time or date specified (or such later time
or date as the Company and the Bookrunner may agree); or (ii) the Placing and
Open Offer Agreement is terminated in the circumstances specified under
"Right to terminate under the Placing and Open Offer Agreement" in the
proposed fundraising announcement released via RNS by the Company at c. 14:04
on 13 February 2026 (the "Launch Announcement"), the Placing will not proceed
and the Placees' rights and obligations hereunder in relation to the Placing
Shares shall cease and terminate at such time and each Placee agrees that no
claim can be made by it or on its behalf (or any person on whose behalf the
Placee is acting) in respect thereof.

Further details of the Open Offer and the terms and conditions on which it is
being made, including the procedure for application and payment, will be
contained in the Circular, which shall be posted to Shareholders and made
available on the Company's website, www.genedrive.com
(http://www.genedrive.com) , in due course.  A further announcement will
confirm the posting date, other key dates in connection with the Fundraising
and the availability of the Circular on the Company's website.

Capitalised terms in this announcement shall, unless the context demands
otherwise, bear the meanings given to such terms in the Launch Announcement.

Total Voting Rights

Following First Admission, the Company's enlarged issued ordinary share
capital will be 1,089,603,992 ordinary shares. This figure may be used by
Shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules.

For further information, please contact:

genedrive plc
 
                  +44 (0) 161 989 0245

Dr Gino Miele (CEO)
 
https://investors.genedrive.com/s/e0025c
(https://investors.genedrive.com/s/e0025c)

Russ Shaw (CFO)

Peel Hunt LLP - Nominated Adviser, Broker and Bookrunner
                        +44 (0) 20 7148 8900

James Steel (Investment Banking)

Sohail Akbar / Nicholas Wilks (ECM)

Wallbrook PR - Financial PR and IR Adviser
                                   +44 (0) 20 7933 8780

Anna Dunphy
                                                                                                or
genedrive@walbrookpr.com

 

About genedrive plc (http://www.genedrive.com (http://www.genedrive.com) )
genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform.  Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes.  Both tests
have undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS.

 The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

 

IMPORTANT NOTICES AND DISCLAIMER

This announcement (the "Announcement") and the information contained in it is
not for publication, release, transmission distribution or forwarding, in
whole or in part, directly or indirectly, in or into the United States of
America, Australia, Canada, Japan or the Republic of South Africa or any other
jurisdiction in which publication, release or distribution would be unlawful.
This Announcement is for information purposes only and does not constitute an
offer to sell or issue, or the solicitation of an offer to buy, acquire or
subscribe for shares in the capital of the Company in the United States of
America, Australia, Canada, Japan or the Republic of South Africa or any other
state or jurisdiction where to do so would be unlawful. Any failure to comply
with these restrictions may constitute a violation of the securities laws of
such jurisdictions. This Announcement has not been approved by London Stock
Exchange or by any other securities exchange.

The new Ordinary Shares, have not been, and will not be, registered under the
U.S. Securities Act of 1933, as amended (the "Securities Act") or with any
securities regulatory authority of any state or other jurisdiction of the
United States of America and may not be offered, sold, pledged, taken up,
exercised, resold, renounced, transferred or delivered, directly or
indirectly, in or into the United States of America absent registration under
the Securities Act, except pursuant to an exemption from the registration
requirements of the Securities Act and in compliance with any applicable
securities laws of any state or other jurisdiction of the United States of
America. The Placing Shares are being offered and sold by the Company outside
of the United States of America in offshore transactions as defined in, and
pursuant to, Regulation S under the Securities Act.

This announcement is not being distributed by, nor has it been approved for
the purposes of section 21 of the Financial Services and Markets Act 2000, as
amended ("FSMA"), by a person authorised under FSMA.  This announcement is
being directed to persons in the United Kingdom only in circumstances in which
section 21(1) of FSMA does not apply.

Members of the Public are not eligible to take part in the Placing.  This
announcement is for information purposes only and is directed only at persons
who are: (1) in Member States of the European Economic Area, qualified
investors as defined in article 2(e) of the Prospectus Regulation (EU)
2017/1129 (the "EU Prospectus Regulation"); (2) in the United Kingdom,
qualified investors as defined paragraph 15 of Part 2 of Schedule 1 to the
Public Offers and Admissions to Trading Regulations 2024 (SI No. 2024/105)(the
"POAT Regulations"), who (A) fall within article 19(5) ("investment
professionals") of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order"), or (B) fall within article
49(2)(a) to (d) ("high net worth companies, unincorporated associations,
etc.") of the Order; or (3) are persons to whom it may otherwise be lawfully
communicated; (all such persons together being referred to as "relevant
persons"). This announcement and the terms and conditions set out herein must
not be acted on or relied on by persons who are not relevant persons. Persons
distributing this announcement must satisfy themselves that it is lawful to do
so. Any investment or investment activity to which this announcement and the
terms and conditions set out herein relates is available only to relevant
persons and will be engaged in only with relevant persons.

The new Ordinary Shares have not been approved, disapproved or recommended by
the U.S. Securities and Exchange Commission, any state securities commission
in the United States of America or any other U.S. regulatory authority, nor
have any of the foregoing authorities passed upon or endorsed the merits of
the offering of new Ordinary Shares. Subject to certain exceptions, the
securities referred to herein may not be offered or sold in the United States
of America, Australia, Canada, Japan or the Republic of South Africa or to, or
for the account or benefit of, any national, resident or citizen of the United
States of America, Australia, Canada, Japan or the Republic of South Africa.

No public offering of securities is being made in the United Kingdom, the
United States of America or any other jurisdiction. Offers of the new Ordinary
Shares will either be made pursuant to an exemption under the EU Prospectus
Regulation and the and the POAT Regulations  (as such terms are defined
above) from the requirement to produce a prospectus or otherwise in
circumstances not resulting in an offer of transferable securities to the
public under section 102B of FSMA.

This Announcement has been issued by, and is the sole responsibility of, the
Company. No representation or warranty, express or implied, is or will be made
as to, or in relation to, and no responsibility or liability is or will be
accepted by the directors or the Company, or by any of its or their respective
partners, employees, advisers, affiliates or agents as to or in relation to,
the accuracy or completeness of this Announcement or any other written or oral
information made available to or publicly available to any interested party or
its advisers, and any liability therefore is expressly disclaimed.   None of
the information in the Announcement has been independently verified or
approved by Peel Hunt or any of its partners, directors, officers, employees,
advisers, consultants, affiliates or agents.

Peel Hunt LLP ("Peel Hunt" or "Bookrunner"), which is authorised and regulated
in the United Kingdom by the FCA is acting as nominated adviser, sole
bookrunner and sole broker to the Company and no one else in connection with
the Placing and is not acting for and will not be responsible to any person
other than the Company for providing the protections afforded to its clients
or for providing advice in relation to the Placing. Peel Hunt's
responsibilities as the Company's nominated adviser under the AIM Rules for
Nominated Advisers are owed solely to London Stock Exchange and are not owed
to the Company or to any Director or to any other person in respect of his
decision to acquire shares in the Company in reliance on any part of this
Announcement.

Except as required under applicable law, neither Peel Hunt nor any of their
directors, officers, partners, members, employees, advisers, affiliates or
agents assume or accept any responsibility whatsoever for the contents of the
information contained in this Announcement or for any other statement made or
purported to be made by or on behalf of Peel Hunt or any of their affiliates
in connection with the Company, the new Ordinary Shares or the Placing.  Peel
Hunt and each of their directors, officers, partners, members, employees,
advisers, affiliates and agents accordingly disclaim all and any
responsibility and liability whatsoever, whether arising in tort, contract or
otherwise (save as referred to above) in respect of any statements or other
information contained in this Announcement and no representation or warranty,
express or implied, is made by Peel Hunt or any of their directors, officers,
partners, employees, advisers, affiliates or agents as to the accuracy,
completeness or sufficiency of the information contained in this Announcement.

The distribution of this Announcement and/or the Placing in certain
jurisdictions may be restricted by law. No action has been taken by the
Company, Peel Hunt or any of their respective affiliates that would, or which
is intended to, permit an offering of the new Ordinary Shares in any
jurisdiction or result in the possession or distribution of this Announcement
or any other offering or publicity material relating to new Ordinary Shares in
any jurisdiction where action for that purpose is required.

This Announcement does not constitute a recommendation concerning any
investor's option with respect to the Placing. Each investor or prospective
investor should conduct his, her or its own investigation, analysis and
evaluation of the business and data described in this Announcement and
publicly available information. The price and value of securities can go down
as well as up. Past performance is not a guide to future performance.   The
contents of this Announcement are not to be construed as legal, business,
financial or tax advice. Each investor or prospective investor should consult
with his or her or its own legal adviser, business adviser, financial adviser
or tax adviser for legal, financial, business or tax advice.

Persons (including without limitation, nominees and trustees) who have a
contractual right or other legal obligations to forward a copy of this
Announcement should seek appropriate advice before taking any action.

Neither the content of the Company's website nor any website accessible by
hyperlinks on the Company's website is incorporated in, or forms part of, this
Announcement.

Product Governance Requirements

Solely for the purposes of the product governance requirements of Chapter 3 of
the FCA Handbook Product Intervention and Product Governance Sourcebook (the
"UK Product Governance Requirements") and/or any equivalent requirements
elsewhere to the extent determined to be applicable, and disclaiming all and
any liability, whether arising in tort, contract or otherwise, which any
"manufacturer" (for the purposes of the UK Product Governance Requirements
and/or any equivalent requirements elsewhere to the extent determined to be
applicable, may otherwise have with respect thereto, the Placing Shares have
been subject to a product approval process, which has determined that the
Placing Shares are: (i) compatible with an end target market of retail
investors and investors who meet the criteria of professional clients and
eligible counterparties, each defined in Chapter 3 of the FCA Handbook Conduct
of Business Sourcebook; and (ii) eligible for distribution through all
permitted distribution channels (the "Target Market Assessment").
Notwithstanding the Target Market Assessment, distributors should note that:
the price of the Placing Shares may decline and investors could lose all or
part of their investment; the Placing Shares offer no guaranteed income and no
capital protection; and an investment in the Placing Shares is compatible only
with investors who do not need a guaranteed income or capital protection, who
(either alone or in conjunction with an appropriate financial or other
adviser) are capable of evaluating the merits and risks of such an investment
and who have sufficient resources to be able to bear any losses that may
result therefrom. The Target Market Assessment is without prejudice to the
requirements of any contractual, legal or regulatory selling restrictions in
relation to the Placing. Furthermore, it is noted that, notwithstanding the
Target Market Assessment, Peel Hunt will only procure investors who meet the
criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of
Chapters 9A or 10A respectively of the FCA Handbook Conduct of Business
Sourcebook; or (b) a recommendation to any investor or group of investors to
invest in, or purchase, or take any other action whatsoever with respect to
the Placing Shares.

Each distributor is responsible for undertaking its own target market
assessment in respect of the Placing Shares and determining appropriate
distribution channels.

Forward Looking Statements

 

This Announcement contains "forward-looking statements" which include all
statements (other than statements of historical facts) including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations, and any statements
preceded by, followed by or that include the words "targets", "believes",
"expects", "aims", "intends", "will", "may", "anticipates", "would", "could"
or "similar" expressions or negatives thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors
beyond the Company's control that could cause the actual results, performance
or achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Group's present and future business strategies and the
environment in which the Group will operate in the future. These
forward-looking statements speak only as at the date of this Announcement. The
Company expressly disclaims any obligation or undertaking to disseminate any
updates or revisions to any forward looking statements contained herein to
reflect any change in the Company's expectations with regard thereto or any
change in events, conditions or circumstances on which any such statements are
based unless required to do so by applicable law or the AIM Rules for
Companies.

 

No statement in this Announcement is intended to be a profit forecast and no
statement in this Announcement should be interpreted to mean that earnings per
share of the Company for the current or future years would necessarily match
or exceed the historical published earnings per share of the Company.

 

This Announcement does not identify or suggest, or purport to identify or
suggest, the risks (direct or

indirect) that may be associated with an investment in the Placing Shares. Any
investment decisions

to buy Placing Shares in the Placing must be made solely on the basis of
publicly available information,

which has not been independently verified by Peel Hunt.

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIQXLFFQLLFBBV



            Copyright 2019 Regulatory News Service, all rights reserved